natgillin/translations-raw huggingface dataset:
Renvela се използва за контролиране на хиперфосфатемия (високи нива на фосфати в кръвта) при: възрастни пациенти на диализа (техника за очистване на кръвта).
Renvela is used to control hyperphosphataemia (high blood phosphate levels) in: adult patients on dialysis (a blood clearance technique).
Renvela съдържа севеламеров карбонат като активно вещество.
Renvela contains sevelamer carbonate as the active ingredient.
Renvela също така е показан за контролиране на хиперфосфатемия при възрастни пациенти с хронично бъбречно заболяване, които не са на диализа, със серумен фосфор > 1,78 mmol/l.
Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/l.
Renvela също така е показан за контролиране на хиперфосфатемия при възрастни пациенти с хронично бъбречно заболяване, които не са на диализа, със серумен фосфор > 1,78 mmol/l.
Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease patients not on dialysis with serum phosphorus > 1.78 mmol/l.
Renvela трябва да се използва в контекста на многостранен терапевтичен подход, който може да включва калциева добавка, 1,25-дихидрокси витамин D3 или един от неговите аналози за контролиране на развитието на бъбречна костна болест.
Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Renvela трябва да се използва заедно с други лекарства като калциеви добавки и витамин D за предотвратяване развитието на костно заболяване.
Renvela should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Renvela трябва да се прилага при бременни жени само в случай на категорична необходимост и след провеждане на внимателен анализ на съотношението риск/полза както за майката, така и за фетуса.
Renvela should only be given to pregnant women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the foetus.
Renvela филмирани таблетки са бели таблетки, от едната страна на които е отпечатано RENVELA 800.
Renvela film-coated tablets are white tablets with RENVELA 800 imprinted on one side.
Renálna eliminácia nezmeneného trabektedínu u človeka je nízka (menej ako 1 %).
Renal elimination of unchanged trabectedin in humans is low (less than 1%).
Renálne toxikologické nálezy boli zistené vo viaccyklových štúdiách toxicity urobených u opíc.
Renal toxicological findings were detected in multi-cycle toxicity studies conducted in monkeys.
Repaglinide Accord 0,5 mg
Repaglinide Accord 0.5 mg
Repaglinide Accord 0,5 mg таблетки
Repaglinide Accord 0.5 mg tablets
Repaglinide Accord 0,5 mg таблетки Repaglinide Accord 1 mg таблетки Repaglinide Accord 2 mg таблетки Репаглинид (Repaglinide)
Repaglinide Accord 0.5 mg tablets Repaglinide Accord 1 mg tablets Repaglinide Accord 2 mg tablets Repaglinide
Repaglinide Accord 0,5 mg таблетки Репаглинид
Repaglinide Accord 0.5 mg tablets Repaglinide
Repaglinide Accord 0,5 mg таблетки са бели до почти бели, кръгли, двойноизпъкнали, със скосен ръб, без покритие, с надпис “R” от едната страна и без надпис от другата.
The Repaglinide Accord 0.5 mg tablet is white to off white, round, biconvex, with beveled edge, with inscription ‘R’ on one side and plain on other side.
Repaglinide Accord 0,5 mg: Всяка таблетка съдържа 0,5 mg репаглинид Repaglinide Accord 1 mg: Всяка таблетка съдържа 1 mg репаглинид Repaglinide Accord 2 mg: Всяка таблетка съдържа 2 mg репаглинид
Repaglinide Accord 0.5 mg: Each tablet contains 0.5 mg repaglinide Repaglinide Accord 1 mg: Each tablet contains 1 mg repaglinide Repaglinide Accord 2 mg: Each tablet contains 2 mg repaglinide
Repaglinide Accord 1 mg таблетки
Repaglinide Accord 1 mg tablets
Repaglinide Accord 1 mg таблетки Репаглинид
Repaglinide Accord 1 mg tablets Repaglinide
Repaglinide Accord 2 mg таблетки
Repaglinide Accord 2 mg tablets
Repaglinide Accord 2 mg таблетки Репаглинид
Repaglinide Accord 2 mg tablets Repaglinide
Repaglinide Accord е „генерично лекарство“.
Repaglinide Accord is a ‘generic medicine’.
Repaglinide Accord не повлиява пряко върху способността за шофиране и работа с машини, но може да предизвика хипогликемия.
Repaglinide Accord has no direct influence on the ability to drive and use machines but may cause hypoglycaemia.
Repaglinide Accord не трябва да се приема при тежко чернодробно заболяване (вижте Не приемайте Repaglinide Accord).
Repaglinide Accord should not be taken if you have a severe liver disease (see Do not take Repaglinide Accord).
Repaglinide Krka 0,5 mg
Repaglinide Krka 0.5 mg
Repaglinide Krka 0,5 mg таблетки Репаглинид
Repaglinide Krka 0.5 mg tablets Repaglinide
Repaglinide Krka 0,5 mg талетки Repaglinide Krka 1 mg таблетки Repaglinide Krka 2 mg таблетки Репаглинид (Repaglinide)
Repaglinide Krka 0.5 mg tablets Repaglinide Krka 1 mg tablets Repaglinide Krka 2 mg tablets Repaglinide
Repaglinide Krka 1 mg таблетки Репаглинид
Repaglinide Krka 1 mg tablets Repaglinide
Repaglinide Krka 2 mg таблетки Репаглинид
Repaglinide Krka 2 mg tablets Repaglinide
Repaglinide Krka е „генерично лекарство“.
Repaglinide Krka is a ‘generic medicine’.
Repaglinide Teva е „генерично лекарство“.
Repaglinide Teva is a ‘generic medicine’.
Repatha 140 mg инжекционен разтвор в предварително напълнена писалка evolocumab (еволокумаб)
Repatha 140 mg solution for injection in pre-filled pen evolocumab
Repatha 140 mg инжекционен разтвор в предварително напълнена писалка еволокумаб
Repatha 140 mg solution for injection in pre-filled pen evolocumab
Repatha 140 mg инжекционен разтвор в предварително напълнена спринцовка
Repatha 140 mg solution for injection in pre-filled syringe
Repatha 140 mg инжекционен разтвор в предварително напълнена спринцовка evolocumab (еволокумаб)
Repatha 140 mg solution for injection in pre-filled syringe evolocumab
Repatha 140 mg инжекционен разтвор в предварително напълнена спринцовка еволокумаб
Repatha 140 mg solution for injection in pre-filled syringe evolocumab
Repatha 140 mg инжекционен разтвор еволокумаб
Repatha 140 mg solution for injection evolocumab
Repatha 140 mg инжекция еволокумаб s.c.
Repatha 140 mg injection evolocumab
Repatha 140 писалка
Repatha 140 pen
Repatha 140 спринцовка
Repatha 140 syringe
Repatha 420 mg веднъж месечно значимо намалява LDL-C от изходното ниво до седмица 12 и седмица 52, в сравнение с контрола (номинална p < 0,001).
Repatha 420 mg once monthly significantly reduced LDL-C from baseline at week 12 and week 52 compared with control (nominal p < 0.001).
Repatha е лекарство, което намалява нивата на „лошия” холестерол - вид мазнина в кръвта.
Repatha is a medicine that lowers levels of ’bad’ cholesterol, a type of fat, in the blood.
Repatha е лекарство, което се използва за лечение на:
Repatha is a medicine used to treat:
Repatha е показан при възрастни с първична хиперхолестеролемия (хетерозиготна фамилна и нефамилна) или смесена дислипидемия, като допълнение към диетата: в комбинация със статин или статин с други понижаващи липидите лечения при пациенти, които не могат да достигнат прицелните стойности на LDL-C с максималната поносима доза статин или, самостоятелно или в комбинация с други понижаващи липидите лечения при пациенти, които имат непоносимост към статини, или при които приложението на статин е противопоказано.
Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Repatha значимо намалява LDL-C от изходното ниво до седмица 12, в сравнение с контрола (номинална p < 0,001).
Repatha significantly reduced LDL-C from baseline at week 12 compared with control (nominal p < 0.001).
Repatha значимо намалява LDL-C от изходното ниво до седмица 12, в сравнение с с контрола (номинална p < 0,001).
Repatha significantly reduced LDL-C from baseline at week 12 compared with control (nominal p < 0.001).
Repatha значимо намалява LDL-C от изходното ниво до средна стойност на седмица 10 и 12 в сравнение с плацебо (p < 0,001).
Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12 compared with placebo (p < 0.001).
Repatha значимо намалява LDL-C от изходното ниво до средна стойност на седмица 10 и 12, в сравнение с плацебо и езетимиб (p < 0,001).
Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p < 0.001).
Repatha значимо намалява TC, ApoB, не-HDL-C, TC/HDL-C, ApoB/ApoA1 VLDL-C, TG и Lp(a) и повишава HDL-C и ApoA1 от изходното ниво до средна стойност на седмица 10 и 12, в сравнение с плацебо (p < 0,05) (вж. таблица 2).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 VLDL-C, TG and Lp(a) and increased HDL-C and ApoA1 from baseline to mean of weeks 10 and 12 compared to placebo (p < 0.05) (see table 2).
Repatha значимо намалява TC, ApoB, не-HDL-C, TC/HDL-C, ApoB/ApoA1 и Lp(a), от изходното ниво до средна стойност на седмица 10 и 12, в сравнение с плацебо и езетимиб (p < 0,001) (вж. таблица 3).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a), from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p < 0.001) (see table 3).
Repatha значимо намалява TC, ApoB, не-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG и Lp(a), и повишава HDL-C и ApoA1 на седмица 52 в сравнение с плацебо (p < 0,001) (таблица 4).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a), and increased HDL-C and ApoA1 at week 52 compared with placebo (p < 0.001) (table 4).
Repatha значително намалява TC, ApoB, не-HDL-C, TC/HDL-C, ApoB/ApoA1 и Lp(a), от изходното ниво до средна стойност на седмица 10 и 12, в сравнение с езетимиб (p < 0,001) (вж. таблица 3).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a), from baseline to mean of weeks 10 and 12 compared to ezetimibe (p < 0.001) (see table 3).
Repatha и в двете дози е ефективен при всички подгрупи в сравнение с плацебо и езетимиб, без да са наблюдавани съществени различия между подгрупите като възраст, раса, пол, регион, индекс на телесна маса, риск според Националната обучителна програма за холестерола, тютюнопушене в момента, изходни рискови фактори за коронарна болест на сърцето (ИБС), фамилна анамнеза за преждевременна ИБС, статус на глюкозен толеранс (т.е. зарахен диабет тип 2, метаболитен синдром или нито едно от двете), хипертония, доза на статина и интензитет, несвързан изходен PCSK9, изходни стойности на LDL-C и изходни стойности на триглицеридите (TG).
Repatha at either dose was effective in all subgroups relative to placebo and ezetimibe, with no notable differences observed between subgroups, such as age, race, gender, region, body-mass index, National Cholesterol Education Program risk, current smoking status, baseline coronary heart disease (CHD) risk factors, family history of premature CHD, glucose tolerance status, (i.e., diabetes mellitus type 2, metabolic syndrome, or neither), hypertension, statin dose and intensity, unbound baseline PCSK9, baseline LDL-C and baseline TG.
Repatha има по-добър ефект от езетимиб при намаляване на LDL-C, TC, ApoB, не-HDL-C, Lp(a), TC/HDL-C, и ApoB/ApoA1.
Repatha was superior to ezetimibe in reducing LDL-C, TC, ApoB, non-HDL-C, Lp(a), TC/HDL-C, and ApoB/ApoA1.
Repatha намалява LDL-C, не-HDL-C, Apo B, TC, Lp(a), VLDL-C, TG, TC/HDL-C, и ApoB/ApoA1 и повишава HDL-C при пациенти със смесена дислипидемия.
Repatha reduced LDL-C, non-HDL-C, Apo B, TC, Lp(a), VLDL-C, TG, TC/HDL-C, and ApoB/ApoA1and increased HDL-C in patients with mixed dyslipidaemia.
Repatha не е изпитван при пациенти с тежко бъбречно увреждане (вж. точка 4.4).
Repatha has not been studied in patients with severe renal impairment (see section 4.4).
Repatha не е изпитван при пациенти с тежко чернодробно увреждане (Child-Pugh клас C) (вж. точка 4.4).
Repatha has not been studied in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.4).
Repatha не повлиява способността за шофиране и работа с машини.
Repatha has no known influence on the ability to drive and use machines.
Repatha не повлиява, или повлиява пренебрежимо способността за шофиране и работа с машини.
Repatha has no or negligible influence on the ability to drive and use machines.
Repatha предварително напълнена писалка SureClick за еднократна употреба
Repatha single use SureClick pre-filled pen
Repatha предварително напълнена писалка трябва да се съхранява в хладилник (2°C до 8°C).
The Repatha pre-filled pen is to be stored in the refrigerator (2°C to 8°C).
Repatha предварително напълнена спринцовка за еднократна употреба
Repatha single use pre-filled syringe
Repatha предварително напълнена спринцовка трябва да се съхранява в хладилник (2°C до 8°C).
The Repatha pre-filled syringe is to be stored in the refrigerator (2°C to 8°C).
Repatha се използва и за лечение на смесена дислипидемия (необичайни нива на мазнини в кръвта, включително високи нива на LDL-холестерол).
Repatha is also used to treat mixed dyslipidaemia (abnormal levels of fats in blood, including high levels of LDL-cholesterol).
Repatha се използва като допълнение към Вашата диета за понижаване на холестерола, ако сте: възрастен с високо ниво на холестерол в кръвта (първична хиперхолестеролемия [хетерозиготна фамилна и нефамилна] или смесена дислипидемия).
Repatha is used in addition to your cholesterol lowering diet if you are: an adult with a high cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial] or mixed dyslipidaemia).
Repatha се предлага под формата на инжекционен разтвор в предварително напълнена спринцовка или предварително напълнена писалка (140 mg).
Repatha is available as a solution for injection in a pre-filled syringe or pre-filled pen (140 mg).
Repatha се прилага заедно с хранителен режим с ниско съдържание на мазнини в следните случаи:
Repatha is to be used together with a low-fat diet, in the following cases:
Repatha трябва да се използва с повишено внимание при пациенти с тежко бъбречно увреждане.
Repatha should be used with caution in patients with severe renal impairment.
Repatha трябва да се използва с повишено внимание при пациенти с тежко чернодробно увреждане.
Repatha should be used with caution in patients with severe hepatic impairment.
Replagal 1 mg/ml концентрат за инфузионен разтвор
Replagal 1 mg/ml concentrate for solution for infusion
Replagal 1 mg/ml концентрат за инфузионен разтвор
Replagal 1 mg/ml concentrate for solution for infusion.
Replagal 1 mg/ml концентрат за инфузионен разтвор Agalsidase alfa
Replagal 1 mg/ml concentrate for solution for infusion agalsidase alfa
Replagal 1 mg/ml стерилен концентрат Agalsidase alfa
Replagal 1 mg/ml sterile concentrate agalsidase alfa
Replagal е предназначен да замени човешкия ензим алфа- галактозидаза A, който липсва при хората с болестта на Фабри.
Replagal is designed to replace the human enzyme alpha-galactosidase A, which is lacking in people with Fabry disease.
Replagal намалява масата на лявата камера средно с 11,5 g, докато при пациентите, получаващи плацебо, има увеличение на масата на лявата камера с 21,8 g.
Replagal reduced left ventricle mass by an average of 11.5 g while patients receiving placebo had an increase in left ventricular mass of 21.8 g.
Replagal не трябва да се прилага едновременно с хлорохин, амиодарон, бенохин или гентамицин, тъй като тези вещества имат потенциала да подтискат вътреклетъчната α- галактозидазна активност.
Replagal should not be co-administered with chloroquine, amiodarone, benoquin or gentamicin since these substances have the potential to inhibit intra-cellular α-galactosidase activity.
Replagal представлява концентрат за инфузионен разтвор.
Replagal is a concentrate for solution for infusion.
Replagal се прилага в доза от 0,2 mg/kg телесно тегло през седмица чрез интравенозна инфузия в продължение на 40 минути.
Replagal is administered at a dose of 0.2 mg/kg body weight every other week by intravenous infusion over 40 minutes.
Reproduction is authorised provided the source is acknowledged
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged
EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
Reproduction is authorised provided the source is acknowledged баланс на организма с цел да предотврати овулация, променя цервикалния мукус и изтънява ендометриума (стената на матката).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. adjusted to suit the patient’s diet, physical activity and lifestyle.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. attaches itself.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. be able to respond more quickly.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. before.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. bisquinolone.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. bodyweight in cats.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. chicks).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. compared with those of placebo (a dummy treatment).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. contents mixed with food.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. control is needed.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. controlling the growth of the lining of the womb.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. cyclooxygenase-2 (COX-2).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. damage.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. day is not recommended.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. delay the dose in patients who experience severe side effects.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. divided into two or three doses.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. each other.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. eye).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. first food or drink of the day.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. from the surface) of a virus called A(H1N1)v 2009.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. glucose levels are high.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. inflammation.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. injection under the skin in the neck.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. internal organs.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. into 2 doses given every 12 hours.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. is available as capsules.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. measles is common.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. month when the dose is increased.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. muscarinic receptors, which control the contraction of muscles.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. nine weeks of age.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. normally attaches itself.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. patients may need 16, 24 or 72 weeks of treatment.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. progression and survival rates as the patients taking tamoxifen.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. replacement.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. study involving 285 patients.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. the maximum number is 4.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. the stomach.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. transcriptase inhibitor’ (NRTI).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. treatment.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. weekly injections followed by monthly maintenance injections.
Reproduction is authorised provided the source is acknowledged.
This solution has to be drunk immediately.
Reproduction is authorised provided the source is acknowledged.
© European Medicines Agency, 2010.
Reproduction is authorised provided the source is acknowledged. аденокарцином на стомаха (вид рак на стомаха) при пациенти, които все още не са лекувани за раковото заболяване.
Reproduction is authorised provided the source is acknowledged. gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer.
Reproduction is authorised provided the source is acknowledged. алергичен дерматит, причинен от бълхи (алергична реакция към ухапване от бълхи).
Reproduction is authorised provided the source is acknowledged. recommended one month after the initial treatment.
Reproduction is authorised provided the source is acknowledged. алфа може да бъде увеличена чрез добавянето му като отделно лекарство през интервали от 7 до
Reproduction is authorised provided the source is acknowledged.